QINGDAO BAHEAL MEDICAL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33 CNY | +2.10% |
|
-2.88% | -7.98% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15,911 | 12,518 | 18,830 | 17,345 | - | - |
| Enterprise Value (EV) 1 | 15,911 | 12,518 | 18,830 | 17,345 | 17,345 | 17,345 |
| P/E ratio | 35.6 x | 24.8 x | 29.2 x | 20.5 x | 15.6 x | 13.1 x |
| Yield | - | - | 2.12% | - | 2.17% | - |
| Capitalization / Revenue | 2.26 x | 1.67 x | 2.49 x | 2.01 x | 1.68 x | 1.47 x |
| EV / Revenue | 2.26 x | 1.67 x | 2.49 x | 2.01 x | 1.68 x | 1.47 x |
| EV / EBITDA | 25.8 x | 17.8 x | 19.9 x | 14 x | 10.5 x | 9.08 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 7.38 x | - | 7.34 x | 5.16 x | 4.48 x | 3.18 x |
| Nbr of stocks (in thousands) | 5,25,100 | 5,25,100 | 5,25,100 | 5,25,613 | - | - |
| Reference price 2 | 30.30 | 23.84 | 35.86 | 33.00 | 33.00 | 33.00 |
| Announcement Date | 25/04/22 | 24/04/23 | 22/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 7,052 | 7,510 | 7,564 | 8,643 | 10,300 | 11,775 |
| EBITDA 1 | - | 617 | 704.3 | 948.5 | 1,236 | 1,652 | 1,911 |
| EBIT 1 | - | 563.9 | 674.3 | 888.1 | 1,143 | 1,517 | 1,776 |
| Operating Margin | - | 8% | 8.98% | 11.74% | 13.22% | 14.73% | 15.08% |
| Earnings before Tax (EBT) 1 | - | 567.9 | 668.5 | 873.6 | 1,135 | 1,509 | 1,767 |
| Net income 1 | 272.7 | 422.8 | 502.1 | 656.3 | 847.4 | 1,112 | 1,319 |
| Net margin | - | 6% | 6.69% | 8.68% | 9.8% | 10.8% | 11.21% |
| EPS 2 | 0.5800 | 0.8500 | 0.9600 | 1.230 | 1.613 | 2.116 | 2.510 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.7620 | - | 0.7150 | - |
| Announcement Date | 23/06/21 | 25/04/22 | 24/04/23 | 22/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 22.9% | 22.8% | 27.3% | 25.3% | 29.6% | 24.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | 11.4% | 15.7% | 13.3% |
| Assets 1 | - | - | - | - | 7,433 | 7,107 | 9,921 |
| Book Value Per Share 2 | - | 4.110 | - | 4.890 | 6.400 | 7.360 | 10.40 |
| Cash Flow per Share 2 | - | 0.3500 | 0.5800 | 1.160 | 1.310 | 1.470 | 1.850 |
| Capex 1 | - | 25.5 | 104 | 123 | 217 | 216 | 216 |
| Capex / Sales | - | 0.36% | 1.39% | 1.63% | 2.51% | 2.1% | 1.83% |
| Announcement Date | 23/06/21 | 25/04/22 | 24/04/23 | 22/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33
CNY
Average target price
48
CNY
Spread / Average Target
+45.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.98% | 2.4B | |
| +19.14% | 71.7B | |
| -3.34% | 23.73B | |
| +10.27% | 9.01B | |
| +12.67% | 8.72B | |
| -17.41% | 8.29B | |
| +13.92% | 5B | |
| +21.40% | 4.48B | |
| -1.41% | 4.08B | |
| -2.13% | 3.92B |
- Stock Market
- Equities
- 301015 Stock
- Financials Qingdao Baheal Medical INC.